Clinical trials: Movement Abnormalities
Idiopathic Parkinson's Disease
Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease Patients
The purpose of this study was to show superiority of Rotigotine over placebo on improvement of depressive symptoms in subjects with idiopathic Parkinson's disease.
- Trial name
- NCT01523301
- Testing
- Rotigotine
- Where
- 29 sites in South Korea
- Volunteers
- 380 people
- Sponsor
- UCB Korea Co., Ltd.
Alzheimer's Disease, Fronto-temporal Dementia
Pilot Trial Evaluating Patient Experience With the MemorEM for Patients With Neurological Diseases
Primary Objective: The primary objective of this pilot study is to gain voluntary feedback from patients with neurological diseases and their caregivers regarding their experiences using the MemorEM head device.
- Conditions
- Alzheimer's Disease, Fronto-temporal Dementia, Parkinson Disease (PD), Cortico Basal Degeneration
- Trial name
- NCT07049341
- Testing
- MemorEM
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- NeuroEM Therapeutics, Inc.
Dyskinesias, Parkinson Disease
Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components
This is a two-part, double-blind, placebo-controlled, randomized, multicenter Phase 2 clinical trial of JM-010 in patients with Parkinson's Disease.
- Trial name
- SHINE (NCT04377945)
- Testing
- Part 1, JM-010 component Group A, Part 1, JM-010 component Group B, Part 1, JM-010 component Group C
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- Bukwang Pharmaceutical
Multiple System Atrophy
A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy
This is a Phase 2, double-blind, placebo-controlled, multi-center, Phase II, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and efficacy of Ya-101 in subjects with multiple system atrophy.
- Trial name
- NCT06848231
- Testing
- YA-101
- Where
- 9 sites in United States, Japan and 1 more
- Volunteers
- 75 people
- Sponsor
- Dasher Neuroscience Inc.
Sialorrhea Secondary to Parkinson's Disease
Safety and Efficacy Study of NH004 Films for Relief of Sialorrhea Symptoms in Parkinson's Disease Patients
The primary goal of the study is to evaluate the safety and potential efficacy of intra-oral dissolvable NH004 films to improve the short-term symptoms of sialorrhea (drooling) in Parkinson's disease (PD) patients.
- Trial name
- NH004-2 (NCT00761137)
- Testing
- 0.3 mg tropicamide, 1 mg tropicamide, 3 mg tropicamide
- Where
- Argentina
- Volunteers
- 19 people
- Sponsor
- NeuroHealing Pharmaceuticals Inc.
Angelman Syndrome, Fragile X Syndrome
Single Dose Pharmacokinetic (PK) Study
The trial is a Phase 1 Single Dose PK Study in Adolescent Subjects with Fragile X syndrome (FXS) or Angelman syndrome (AS). The primary objective of the study is to evaluate the pharmacokinetics (PK) of OV101 following a single 5…
- Trial name
- NCT03109756
- Testing
- OV101
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Ovid Therapeutics Inc.
Parkinson's Disease
ExAblate Transcranial MRgFUS for Unilateral Pallidotomy for the Treatment of Parkinson's Disease
The proposed study is to evaluate the safety and initial effectiveness of the ExAblate Transcranial MRgFUS) treatment of patients with L-dopa induced dyskinesia of Parkinson's disease (LID PD).
- Trial name
- NCT02347254
- Testing
- Transcranial ExAblate
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- InSightec
Parkinson's Disease
A Study to Evaluate the Safety, Tolerability, PK and PD of HNC364 Injectable Suspension
This is a non-randomized, dose-escalation first-in-human study to evaluate the safety, tolerability, PK, and PD of HNC364 following intramuscular administration of single ascending doses.
- Trial name
- NCT05523570
- Testing
- HNC364
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Guangzhou Henovcom Bioscience Co. Ltd.
Essential Tremor
A Clinical Trial of PRAX-114 in Participants With Essential Tremor
This is a 2-part clinical trial to evaluate the safety, tolerability, pharmacokinetics, and efficacy of PRAX-114 in participants with essential tremor (ET).
- Trial name
- NCT05387642
- Testing
- 10 mg PRAX-114 or 20 mg PRAX-114
- Where
- 3 sites in United States
- Sponsor
- Praxis Precision Medicines
Parkinsons Disease
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease
This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on…
- Trial name
- PADOVA (NCT04777331)
- Testing
- Prasinezumab
- Where
- 110 sites in United States, Austria and 7 more
- Volunteers
- 586 people
- Sponsor
- Hoffmann-La Roche
Parkinson Disease
Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States:
Real-World Participants Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States: A Prospective, Phase 4, Multicenter, Observational Study in Parkinson's Disease
- Trial name
- NCT07219927
- Testing
- Observational study
- Where
- 5 sites in United States
- Volunteers
- 120 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Parkinson's Disease (PD)
Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person.
- Trial name
- NCT04380142
- Testing
- ABBV-951, Levodopa/Carbidopa (LD/CD)
- Where
- 76 sites in United States, Australia
- Volunteers
- 174 people
- Sponsor
- AbbVie
Parkinson Disease
Adaptive Deep Brain Stimulation (aDBS) Study (Early Adapter) Part II
The purpose of the study is to evaluate the efficacy of aDBS (preferred mode, single or dual threshold) vs standard continuous DBS (cDBS) in decreasing Total Electrical Energy Delivered (TEED).
- Trial name
- NCT07106242
- Testing
- Adaptive DBS, cDBS
- Where
- 2 sites in Japan
- Volunteers
- 25 people
- Sponsor
- MedtronicNeuro
Advanced Parkinson's Disease
Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease
The primary objective of this study is to provide continued access to levodopa-carbidopa intestinal gel (LCIG), to participants who have already participated in an open-label efficacy and safety study with the same treatment…
- Trial name
- NCT00660673
- Testing
- Levodopa-Carbidopa Intestinal Gel (LCIG), CADD-Legacy® 1400 ambulatory infusion pump, Percutaneous Endoscopic Gastrostomy with jejunal extension tube (PEG-J)
- Where
- 61 sites in United States, Australia and 9 more
- Volunteers
- 262 people
- Sponsor
- AbbVie
PARKINSON DISEASE (Disorder)
Open-Label, Multi-Stage Study to Optimize the Intraputaminal Administration of AB-1005 Using a Prescriptive Infusion Algorithm (PIA)
This study is being done to test a new way of delivering AB-1005 into the brain. The goal is to make the procedure easier and quicker to perform, while providing similar amounts of drug to the part of the brain that needs…
- Trial name
- PIA (NCT07215403)
- Testing
- Prescriptive Infusion Algorithm, AB-1005
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- AskBio Inc
Parkinson Disease
A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)
To demonstrate efficacy and dose-response of NS 2330 versus placebo in patients with early Parkinson's Disease in 14 weeks of treatment, and to investigate the safety and tolerability of NS 2330 in these patients.
- Trial name
- NCT00148486
- Testing
- NS 2330
- Where
- 55 sites in United States, Canada
- Volunteers
- 261 people
- Sponsor
- Boehringer Ingelheim
Progressive Supranuclear Palsy, Corticobasal Syndrome
Rho Kinase (ROCK) Inhibitor in Tauopathies - 1
A Phase 2a Open-Label Preliminary Safety, Tolerability, and Biomarker Study of Oral Fasudil in Patients with the 4-Repeat Tauopathies of Progressive Supranuclear Palsy-Richardson Syndrome or Corticobasal Syndrome
- Trial name
- ROCKIT-1 (NCT04734379)
- Testing
- Fasudil
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Woolsey Pharmaceuticals
Huntington Disease
Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease
Huntington disease (HD) is an inherited neurodegenerative disease which affects over 30,000 people in both the United States and Australia.
- Trial name
- Reach2HD (NCT01590888)
- Testing
- PBT2
- Where
- 19 sites in United States, Australia
- Volunteers
- 109 people
- Sponsor
- Prana Biotechnology Limited
Dementia With Lewy Bodies
A Study to Assess Safety, Tolerability, and Efficacy of HTL0018318 in Patients With Dementia With Lewy Bodies
To establish the safety and efficacy of HTL0018318 compared with placebo when administered once daily for 12 weeks to patients with dementia with Lewy bodies.
- Trial name
- DLB (NCT03592862)
- Testing
- HTL0018318
- Where
- 3 sites in Japan
- Sponsor
- Nxera Pharma UK Limited
Parkinson Disease
Automated Deep Brain Stimulation Programming Using Functional Mapping
Participants will undergo DBS programming guided by the DBS-Expert system and by a clinician per standard care.
- Trial name
- DBS-Expert (NCT02765282)
- Testing
- Algorithm based programming using Kinesia-based assessment
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Great Lakes NeuroTechnologies Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.